[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100403635":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":40,"collaborators":7,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":7,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Showa Inan General Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","serum leucine-rich alpha-2 glycoprotein (LRG) levels","Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Akira Horiuchi, MD","CONTACT","81265822121","3012","horiuchi.akira@sihp.jp",{"name":21,"role":16,"phone":17,"phoneExt":18,"email":22},"Masashi Kajiyama, MD","kajiyama.masashi@sihp.jp",[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Komagane","Nagano","399-4117","Japan","JP",{"type":32,"coordinates":33},"Point",[34,35],137.93745,35.71657,{"lat":35,"lon":34},[38],{"name":39,"role":16,"phone":7,"phoneExt":7,"email":7},"Yamaguchi Yukari",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Akira Horiuchi","Chief","100403635","effectiveness-of-serum-leucine-rich-alpha-2-glycoprotein-levels-on-ibd-100403635",false,"NCT04535882","Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD","Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis","Inclusion Criteria:\n\n* Patients whom possible UC or Crohn disease was suspected\n\nExclusion Criteria:\n\n* other autoimmune diseases\n* acute or chronic renal failure\n* chronic heart diseases\n* liver cirrhosis\n* cancer\n* acute or chronic infections\n* ischemic colitis\n* infectious colitis","ALL",{"count":53,"type":54},300,"ESTIMATED","OBSERVATIONAL","We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.",[58],"LRG Levels","2026-05-09",{"date":61,"type":62},"2026-05-13","ACTUAL",{"date":64,"type":62},"2020-10-01",{"date":66,"type":54},"2026-12-31",{"name":5,"class":6},1]